$SYBX

Synlogic Inc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$1.1 -

Extented Hours

VOLUME

98,657

DAY RANGE

1.07 - 1.14

52 WEEK

1.02 - 4.54

Join Discuss about SYBX with like-minded investors

profile
@dros #droscrew
recently

Upgrades 11/24: $AEG $CVX $DEO $DLTR $FMX $GRUB $SYBX $YSG .. Downgrades 11/24: $BABA $BBY $GPS $HTA $JACK $JWN $NOAH $PLAN $RPM $TITN +Initiations 11/24: $AURA $AVY $BFRI $BTTX $CFG $DSEY $GPK $LIAN $MYNA $OCUP $PLRX $SLGN $SPAQ $SPOT $TRDA .. -Initiations 11/24:

77 Replies 14 πŸ‘ 11 πŸ”₯

profile
@nepestheone #StockTraders.NET
recently

MIC WATCHLIST SDC - Looking for a morning pop to scale in short 7.50 / 8.00 VSTM - Ideally 3.50 / 3.70 / 4.00 to scale in 30% max size until confirmation. STOP over 4.15 SYBX - Watching for a volume rush at open due to ETB. Will let this trade out.. Waiting for a death candle then will attack HLBZ - Would love a r/g rejection to short this. Mostly reactive as SSR will turn on at open CRVS - Wouldn't be surprised to see this go red and immediately reclaim and trap. For me will look for a 6.00 / 6.50 rejection to get involved ZEVO - SSR is on. Maybe a 6.50 / 7.00 / 7.50 push to scale in. stop is over pre mkt HOD. 30% max size until confirm EDSA - ETB. Potential runner of the day. Ignoring it for now APRE - 6.00 / 6.50 line

101 Replies 6 πŸ‘ 12 πŸ”₯

profile
@Navneet #droscrew
recently

$sybx popped

107 Replies 10 πŸ‘ 12 πŸ”₯

Key Metrics

Market Cap

77.28 M

Beta

0.96

Avg. Volume

173.98 K

Shares Outstanding

70.25 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-11

Next Dividend Date

Company Information

Synlogicβ„’ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic therapeutics that target validated underlying biology to treat disease in new ways. Synlogic's proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX). The company is also building a portfolio of partner-able assets in immunology and oncology.

CEO: Aoife Brennan

Website:

HQ: 301 Binney St Ste 402 Cambridge, 02142-1030 Massachusetts

Related News